Merck & Co., Inc. (MRK) Tops Q4 EPS by 2c; Guides In-Line
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil pares losses as market weighs Saudi supply concerns, Middle East tensions
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Leerink Swann Downgrades Merck (MRK) to Market Perform
February 4, 2013 7:20 AM ESTLeerink Swann downgraded Merck (NYSE: MRK) from Outperform to Market Perform.
The firm cited: "(1) reduced prospects with the delay/uncertainty around odanacatib, (2) increasing 2013+ competition vs. Januvia & Isentress as well as the outcome of Germany's (G-BA/AMNOG) planned assessment of DPP-IV inhibitors, (3) ongoing investor... More
